Compare DGII & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DGII | CDNA |
|---|---|---|
| Founded | 1985 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.0B |
| IPO Year | 1995 | 2007 |
| Metric | DGII | CDNA |
|---|---|---|
| Price | $47.23 | $16.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $48.80 | $27.33 |
| AVG Volume (30 Days) | 228.0K | ★ 520.3K |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.05 | N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $430,221,000.00 | $48,324,000.00 |
| Revenue This Year | $18.71 | $16.01 |
| Revenue Next Year | $7.22 | $11.31 |
| P/E Ratio | $153.15 | ★ N/A |
| Revenue Growth | 1.46 | ★ 18.93 |
| 52 Week Low | $22.39 | $10.96 |
| 52 Week High | $51.78 | $21.49 |
| Indicator | DGII | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 44.03 | 38.86 |
| Support Level | $42.69 | $16.62 |
| Resistance Level | $47.86 | $17.09 |
| Average True Range (ATR) | 1.71 | 0.73 |
| MACD | -0.35 | 0.04 |
| Stochastic Oscillator | 5.53 | 17.91 |
Digi International Inc is a Minnesota corporation that provides business and mission-critical Internet of Things (IoT) connectivity products and services. It operates through two segments: IoT Products & Services, which supports OEMs, enterprise, and government customers in deploying secure IoT connectivity solutions, and IoT Solutions, consisting of SmartSense and its Managed Network-as-a-Service (MNaaS) business offering wireless temperature and condition-based monitoring, employee task management, label printing, and other services. The company generates the majority of its revenue from the IoT Products & Services segment and mainly from the United States, with a presence in Europe, the Middle East and Africa, and the Rest of the world.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.